INFORM2 NivEnt: a clinical study for children with relapsing cancer
The INFORM2 NivEnt study, an innovative targeted treatment for cancer resistant to conventional therapies
Some children suffer from recurrent and refractory cancer for whom conventional anti-tumor therapies are no longer effective. This is why the INFORM2 NivEnt study is testing a combination of two new drugs in some of these children:
- Nivolumab: not only does it prevent cancer cells from hiding from the immune system, it also helps the immune system to attack cancer cells.
- Entinostat: modifies the structure of gene molecules in cancer cells to halt tumor growth.
In laboratory experiments with tumor cells, these drugs work particularly well when combined. However, this combination has not yet been evaluated in humans.
In the INFORM2 NivEnt study, patients were treated with both drugs. Efficacy against the disease has been established.
Complementary research will also be carried out. The aim is to understand how different groups of patients react according to the biological characteristics of their tumor.
For further information, please consult medical journal about INFORM2 NivEnt.
Zoé4life has funded INFORM2 NivEnt to the tune of CHF 62,700.-, thanks to funds raised at our Move4life event in March 2021. This therapy will soon be available for children in Switzerland.
Together we can make a difference
There are many ways to support us. Your commitment makes a difference for children with cancer.
